About Us
Company Overview
Board of Directors
Management Team
Organization Structure
Pipeline
Pipeline
OBI-858
Investors
Announcements
Event Calendar
News & Events
Careers
Contact Us
繁體中文
繁體中文
About Us
Company Overview
Board of Directors
Management Team
Organization Structure
Pipeline
Pipeline
OBI-858
Investors
Announcements
Event Calendar
News & Events
Careers
Contact Us
Contact Us
Announcements
2025.03.20
OBIGEN PHARMA has achieved the objectives of interim analysis for Phase 2 clinical trial of OBI-858
2025.02.18
OBIGEN Pharma Appoints New CEO to Lead IPO Growth
2024.11.11
OBIGEN and A Phase I Clinical Trial Physician Present New 760 kDa Taiwan Botulinum Toxin at AMWC Japan 2024
2024.10.02
OBI-858 Approved by INTELLECTUAL PROPERTY CORPORATION OF MALAYSIA (MyIPO), No. MY-205101-A
2024.09.30
OBI-858 Approved by TAIPEI GRAND MOSQUE FOUNDATION For Halal Certificate No. TGM.N13-240702-250831-01B55-1
2024.05.27
OBI-858 Approved by Indonesia DIRECTORATE GENERAL OF INTELLECTUAL PROPERTY, No. HKI-3-KI.05.01.08-DP-P00202109681
2024.05.03
TFDA CLEARS OBI-858’S IND APPLICATION FOR PHASE II HUMAN CLINICAL TRIAL
2024.03.04
Filing of Phase II Human Clinical Trial Application for OBI-858 to Taiwan Food and Drug Administration (TFDA)
2024.02.19
OBI-858 Approved by Saudi Authority for Intellectual Property (SAIP), No.521430958
2023.12.29
Institutional Director of OBI Pharma Changes Its Representative
1